http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 08 Sep 2026 07:30:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/BriaCell+adds+Memorial+Sloan+Kettering+to+Phase+3+breast+cancer+trial/27033226.html <p>BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced that Memorial Sloan Kettering Cancer Center (MSK) has joined its ongoing pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer.</p> <p>The trial, identified as NCT06072612, now spans more than 80 active clinical sites across 15 states. Other participating institutions include Penn Medicine's Abramson Cancer Center, Mayo Clinic, Northwestern University, Smilow Cancer Hospital at Yale New Haven, and Sylvester Comprehensive Cancer Center, among others.</p> <p>The study, known as the Bria-ABC study, compares the Bria-IMT combination regimen against physician's choice of treatment in patients with advanced metastatic http://www.streetinsider.com/FDA/BriaCell+adds+Memorial+Sloan+Kettering+to+Phase+3+breast+cancer+trial/27033226.html Tue, 08 Sep 2026 07:30:28 -0400 BCT BCTX http://www.streetinsider.com/FDA/BriaCell+adds+Memorial+Sloan+Kettering+to+Phase+3+breast+cancer+trial/27033226.html <p>BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced that Memorial Sloan Kettering Cancer Center (MSK) has joined its ongoing pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer.</p> <p>The trial, identified as NCT06072612, now spans more than 80 active clinical sites across 15 states. Other participating institutions include Penn Medicine's Abramson Cancer Center, Mayo Clinic, Northwestern University, Smilow Cancer Hospital at Yale New Haven, and Sylvester Comprehensive Cancer Center, among others.</p> <p>The study, known as the Bria-ABC study, compares the Bria-IMT combination regimen against physician's choice of treatment in patients with advanced metastatic http://www.streetinsider.com/FDA/BriaCell+adds+Memorial+Sloan+Kettering+to+Phase+3+breast+cancer+trial/27033226.html Tue, 08 Sep 2026 07:30:28 -0400 BCT BCTX http://www.streetinsider.com/Press+Releases/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html <ul type="disc"><li style="text-align:left;"><strong><em>Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)</em></strong></li><li style="text-align:left;"><strong><em>BriaCell Phase 3 trial <a href="https://feeds.issuerdirect.com/news-release.html?newsid=8024473194415951&amp;symbol=BCTX" rel="nofollow" target="_blank">featured in Nature Medicine</a> as “Eleven clinical trials that will shape medicine in 2026”<br /><br /></em></strong></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast http://www.streetinsider.com/Press+Releases/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html Tue, 08 Sep 2026 07:30:00 -0400 BCT BCTX http://www.streetinsider.com/Press+Releases/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html <ul type="disc"><li style="text-align:left;"><strong><em>Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)</em></strong></li><li style="text-align:left;"><strong><em>BriaCell Phase 3 trial <a href="https://feeds.issuerdirect.com/news-release.html?newsid=8024473194415951&amp;symbol=BCTX" rel="nofollow" target="_blank">featured in Nature Medicine</a> as “Eleven clinical trials that will shape medicine in 2026”<br /><br /></em></strong></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast http://www.streetinsider.com/Press+Releases/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html Tue, 08 Sep 2026 07:30:00 -0400 BCT BCTX http://www.streetinsider.com/Globe+Newswire/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html <ul type="disc"><li style="text-align:left;"><strong><em>Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)</em></strong></li><li style="text-align:left;"><strong><em>BriaCell Phase 3 trial <a href="https://feeds.issuerdirect.com/news-release.html?newsid=8024473194415951&amp;symbol=BCTX" rel="nofollow" target="_blank">featured in Nature Medicine</a> as “Eleven clinical trials that will shape medicine in 2026”<br /><br /></em></strong></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast http://www.streetinsider.com/Globe+Newswire/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html Tue, 08 Sep 2026 07:30:00 -0400 BCT BCTX http://www.streetinsider.com/Globe+Newswire/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html <ul type="disc"><li style="text-align:left;"><strong><em>Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)</em></strong></li><li style="text-align:left;"><strong><em>BriaCell Phase 3 trial <a href="https://feeds.issuerdirect.com/news-release.html?newsid=8024473194415951&amp;symbol=BCTX" rel="nofollow" target="_blank">featured in Nature Medicine</a> as “Eleven clinical trials that will shape medicine in 2026”<br /><br /></em></strong></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast http://www.streetinsider.com/Globe+Newswire/BriaCell%E2%80%99s+Pivotal+Phase+3+Metastatic+Breast+Cancer+Study+Expands+to+Leading+Cancer+Center/27033187.html Tue, 08 Sep 2026 07:30:00 -0400 BCT BCTX http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543